FDA approves drug for tough-to-treat type of leukemia

TRENTON, N.J. (AP) - The U.S. Food and Drug Administration has approved a new drug targeting a subset of leukemia patients with a genetic abnormality that makes the cancer harder to treat.

It approved sales of Venclexta (VEHN'-clecks-tah) for patients with chronic lymphocytic leukemia who relapsed or weren't helped by a prior treatment and are missing the part of chromosome 17 that kills cancer cells.

FDA approves drug for tough-to-treat type of leukemia